490 related articles for article (PubMed ID: 23289892)
1. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.
Meng H; Mai WX; Zhang H; Xue M; Xia T; Lin S; Wang X; Zhao Y; Ji Z; Zink JI; Nel AE
ACS Nano; 2013 Feb; 7(2):994-1005. PubMed ID: 23289892
[TBL] [Abstract][Full Text] [Related]
2. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.
Meng H; Liong M; Xia T; Li Z; Ji Z; Zink JI; Nel AE
ACS Nano; 2010 Aug; 4(8):4539-50. PubMed ID: 20731437
[TBL] [Abstract][Full Text] [Related]
3. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
4. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
5. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment.
Wang D; Xu X; Zhang K; Sun B; Wang L; Meng L; Liu Q; Zheng C; Yang B; Sun H
Int J Nanomedicine; 2018; 13():187-198. PubMed ID: 29343957
[TBL] [Abstract][Full Text] [Related]
6. Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier.
Li JM; Zhang W; Su H; Wang YY; Tan CP; Ji LN; Mao ZW
Int J Nanomedicine; 2015; 10():3147-62. PubMed ID: 25960653
[TBL] [Abstract][Full Text] [Related]
7. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Efficacy against Drug-Resistant Tumors Enabled by Redox-Responsive Mesoporous-Silica-Nanoparticle-Supported Lipid Bilayers as Targeted Delivery Vehicles.
Yang S; Zhang B; Zhao X; Zhang M; Zhang M; Cui L; Zhang L
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791591
[TBL] [Abstract][Full Text] [Related]
9. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
[TBL] [Abstract][Full Text] [Related]
10. A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy.
Shen W; Liu W; Yang H; Zhang P; Xiao C; Chen X
Biomaterials; 2018 Sep; 178():706-719. PubMed ID: 29433753
[TBL] [Abstract][Full Text] [Related]
11. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
12. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
[TBL] [Abstract][Full Text] [Related]
13. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
Shen J; He Q; Gao Y; Shi J; Li Y
Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
[TBL] [Abstract][Full Text] [Related]
16. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
[No Abstract] [Full Text] [Related]
17. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.
Chen Y; Bathula SR; Li J; Huang L
J Biol Chem; 2010 Jul; 285(29):22639-50. PubMed ID: 20460382
[TBL] [Abstract][Full Text] [Related]
18. Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic Breast Cancer.
Zhuang J; Chen S; Hu Y; Yang F; Huo Q; Xie N
Int J Nanomedicine; 2021; 16():1961-1976. PubMed ID: 33727809
[TBL] [Abstract][Full Text] [Related]
19. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers.
Huang W; Lang Y; Hakeem A; Lei Y; Gan L; Yang X
Int J Nanomedicine; 2018; 13():1723-1736. PubMed ID: 29606866
[TBL] [Abstract][Full Text] [Related]
20. Polydopamine coated hollow mesoporous silica nanoparticles as pH-sensitive nanocarriers for overcoming multidrug resistance.
Shao M; Chang C; Liu Z; Chen K; Zhou Y; Zheng G; Huang Z; Xu H; Xu P; Lu B
Colloids Surf B Biointerfaces; 2019 Nov; 183():110427. PubMed ID: 31408782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
